期刊文献+

星形细胞胶质瘤中IDH1基因突变及DNA甲基化分析 被引量:7

IDH1 mutation and DNA methylation of astrocytic glioma patients
原文传递
导出
摘要 目的分析星形细胞胶质瘤患者IDH1基因突变分布与病理级别、预后的关系;探讨DNA甲基化是否为IDH1基因调控的模式之一。方法直接测序法检测91例星形细胞胶质瘤组织样本中IDH1的突变分布;重亚硫酸盐测序法检测9例星形细胞胶质瘤中IDH1启动子DNA甲基化水平。结果91例星形细胞胶质瘤患者中35例存在IDH1突变(38.5%),均为R132H突变。WHOI级肿瘤中未检测到IDH1突变;WHOⅡ-Ⅳ级原发性星形细胞胶质瘤中IDH1突变率分别为70.6%、62.1%、12.5%,突变率与病理级别呈负相关(r=0.522,P〈0.001);7例继发性多形性胶质母细胞瘤中有5例(71.4%)发生突变,突变类型与原发肿瘤一致。IDH1突变型胶质瘤患者中位生存期较IDH1野生型患者明显延长(P〈0.05)。9例胶质瘤患者IDH1启动子均未检测到DNA甲基化改变。结论IDH1突变在星形细胞胶质瘤中发生频繁,是预后改善的指标;DNA甲基化可能未参与IDH1基因表达的调控。 Objective To investigate the relationship between isocitrate dehydrogenase 1 ( IDH1 ) gene mutation and the pathological grade and prognosis in astrocytic glioma patients. And to identify whether DNA methylation is one of the IDH1 gene regulatory patterns. Methods IDH1 mutation was detected by direct sequencing in 91 astrocytic glioma tissue samples; DNA methylation of IDH1 promoter was detected by bisulfite sequencing in 9 astrocytic glioma cases. Results IDH1 mutations were demonstrated in 35 of 91 cases (38.5%) and all mutations were the type of R132H. No mutation of IDH1 was detected in WHO grade I astrocytoma. Frequent mutations of IDH1 were observed as 70. 6% in primary WHO grade 1I astrocytoma, 62. 1% in primary WHO grade 11I astrocytoma, 12. 5% in primary glioblastoma multiforme. Frequencies of IDH1 mutations were negatively correlated with WHO pathological grade Ⅱ-Ⅳ of primary astrocytic glioma ( r =0. 522, P 〈 0. 001 ). IDH1 mutations were found in 5 of 7 secondary glioblastomas (71.4%), and the type of mutation was consistent with that in primary tumors. The mutation of the IDH1 was significantly associated with better outcome in the patients of astrocytic gliomas ( P 〈 0. 05 ). DNA methylation of IDH1 promoter was not found in 9 glioma patients. Conclusions IDH1 mutation occured frequently in astrocytic gliomas and is a favorable prognostic indicator. DNA methylation might not be involved in the regulation of IDH1 gene expression.
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第3期255-258,共4页 Chinese Journal of Neurosurgery
基金 国家自然科学基金青年基金(81201975) 江苏省自然科学基金青年基金(BK2012224) 江苏省高校自然科学研究面上项目(11KJB320010) 江苏省卫生厅面上项目(11201124) 南通大学医学院自然科学基金(YXY2010-14) 江苏省“六大人才高峰”资助项目(2011-WS-065)
关键词 神经胶质瘤 异柠檬酸脱氢酶1 突变 DNA甲基化 Glioma IDH1 Mutation DNA methylation
  • 相关文献

参考文献14

  • 1Tawa R, Ono T, Kurishita A, et al. Changes of DNA methylation level during pre- and postnatal periods in mice. Differentiation, 1990,45:44- 48.
  • 2Jennings GS, Sechi P, Stevenson R, et al. Cytosolic NADP- dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J Biol Chem , 1994,269 : 23128-23134.
  • 3Verhoeven NM, Jakobs C. Human metabolism of phytanic acid and pristanic acid. Prog Lipid Res ,2001,40: 453- 466.
  • 4Parsons DW. An integrated genomie analysis of human gliobla- stoma muhiforme. Science, 2008, 321: 1807.
  • 5Sanson M, Marie Y, Paris S, et al. lsocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol ,2009, 27:4150-4.
  • 6Yah H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med ,2009,360:765-773.
  • 7袁浩,袁先厚,江普查,张捷,文志华.异柠檬酸脱氢酶基因突变在神经胶质瘤发生发展中的作用[J].中华实验外科杂志,2011,28(5):737-739. 被引量:7
  • 8袁浩,袁先厚,江普查,张捷,俞苏寰,陈新军,曹长军,赵时雨,文志华.胶质母细胞瘤与IDH1基因突变的关系[J].武汉大学学报(医学版),2011,32(2):164-166. 被引量:3
  • 9Wei Yan, Wei Zhang, Gan You, et al. Correlation of IDH1 Mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One, 2012,7:1-6.
  • 10徐国政,杜浩,高宝成,张新元,文雪,宋健,黄河,袁先厚.恶性脑胶质瘤预后相关多因素分析[J].中华神经外科杂志,2011,27(10):1040-1044. 被引量:10

二级参考文献47

共引文献18

同被引文献60

  • 1高燕,张厚德,林菊生.人肝癌组织父系表达基因10印记状态与差异性DNA甲撼化区甲基化状态的关系[J].中华消化杂忠,2013:33(4):279-80.
  • 2Kristensen DG, Skakkebaek NE, Rajpert-De Meyts E. Epigenetic fea- tures of testicular germ cell tumours in relation to epigenetic characteris- tics of foetal germ cells[ J]. lnt J Dev Biol,2013 ;57(4) :309-17.
  • 3Van Der Zwan YG, Stoop H, Rossello F. Role of epigenetics in the etiol- ogy of germ cell cancer[J]. Int J Dev Biol,2013 ;57(4) :299-308.
  • 4Heyn H, Mandez-Gonza1ez J. Epigenetic profiling joins personalized cancer medicine [ J ]. Expert Rev Mol Diagn ,2013 ; 13 ( 5 ) :473-9.
  • 5Belharazem D, Kirchner M, Geissler F. Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer [ J]. Endocr Connect,2012 ; 1 ( 2 ) : 87-94.
  • 6Yu SL, Su SY, Li QF. Duplicated CCAAT/enhancer-binding protein 13 (C/EBPI3) gene: Transcription and methylation changes in response to dietary betaine in Landes goose liver[ J]. Pouh Sci ,2013 ;92(7) :1878-87.
  • 7Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define theprognosis and molecular profiles of patients with gliomas: ameta-analysis [J]. PLoS One, 2013, 8(7): e68782.
  • 8Lewandowska M A, Furtak J, Szylberg T, et al. An analysisof the prognostic value of IDH1 (isocitrate dehydrogenase 1)mutation in polish glioma patients [J]. Mol Diagn Ther,2013,Epub ahead of print.
  • 9Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitratedehydrogenase-1 mutations: a fundamentally new under-standing of diffuse glioma [J]. Lancet Oncol, 2011,12: 83-91.
  • 10Bolduc JM, Dyer DH, Scott WG, et al. Mutagenesis and lanestructures of enzyme intermediates: isocitrate dehydroge-nase [J]. Science, 1995, 268: 1312-1318.

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部